Table 1 Investigation of monoclonal antibodies or small molecule inhibitors targeting the CD39/CD73/A2AR pathway in clinical trials. (https://clinicaltrials.gov/)
Agent/drug | Company | Mechanism | Phase | NCT number |
|---|---|---|---|---|
JS019 | Suzhou Kebo Ruijun Biotechnology Co, Ltd | Anti-CD39 monoclonal antibody | Phase I | NCT05508373 |
ES014 | Elpiscience Biopharma, Ltd. | Anti-CD39/TGF-β bispecific antibody | Phase I | NCT05381935 |
PUR001 | Purinomia Biotech, Inc. | Anti-CD39 monoclonal antibody | Phase I | NCT05234853 |
IPH5201 | MedImmune LLC | CD39 antagonist | Phase I | NCT04261075 |
SRF617 | Surface Oncology | CD39 antagonist | Phase I | NCT04336098 |
ES002023 | Elpiscience Biopharma, Ltd. | CD39 antagonist | Phase I | NCT05075564 |
TTX-030 | Trishula Therapeutics, Inc. | CD39 antagonist | Phase I | NCT03884556 |
PT199 | Phanes Therapeutics | Anti-CD73 monoclonal antibody | Phase I | NCT05431270 |
IPH5301 | Institut Paoli-Calmettes | Anti-CD73 antibody | Phase I | NCT05143970 |
TJ004309 | I-Mab Biopharma US Limited | Anti-CD73 antibody | Phase II | NCT05001347 |
JAB-BX102 | Jacobio Pharmaceuticals Co., Ltd. | Anti-CD73 monoclonal antibody | Phase I | NCT05174585 |
CPI-006 | Corvus Pharmaceuticals, Inc. | Anti-CD73 antibody | Phase I | NCT03454451 |
AK119 | Akeso | Anti-CD73 antibody | Phase I | NCT05173792 |
Sym024 | Symphogen A/S | Anti-CD73 antibody | Phase I | NCT04672434 |
IBI325 | Innovent Biologics (Suzhou) Co. Ltd. | Anti-CD73 antibody | Phase I | NCT05119998 |
Dalutrafusp (GS-1423) | Gilead Sciences | Anti-CD73-TGFβ-Trap bifunctional Antibody | Terminated | NCT03954704 |
HLX23 | Shanghai Henlius Biotech | CD73 antagonist | Phase I | NCT04797468 |
AB680 | Arcus Biosciences, Inc | CD73 antagonist | Phase I | NCT04104672 |
LY3475070 | Eli Lilly and Company | CD73 antagonist | Phase I | NCT04148937 |
MEDI9447 (oleclumab) | AstraZeneca | CD73 antagonist | Phase I | NCT03736473 |
NZV930 | Novartis Pharmaceuticals | CD73 antagonist | Phase I | NCT03549000 |
INCA 0186 | Incyte Corporation | CD73 antagonist | Phase I | NCT04989387 |
BMS-986179 | Bristol-Myers Squibb | CD73 antagonist | Phase I | NCT02754141 |
ORIC-533 | ORIC Pharmaceuticals | CD73 antagonist | Phase I | NCT05227144 |
TT-10 | Tarus Therapeutics, Inc. | A2AR antagonist | Phase II | NCT04969315 |
Ciforadenant (CPI-444) | M.D. Anderson Cancer Center | A2AR antagonist | Phase Ib/II | NCT05501054 |
PBF-509 | Palobiofarma SL | A2AR antagonist | Phase I | NCT02403193 |
Taminadenant (NIR178) | Novartis Pharmaceuticals | A2AR antagonist | Phase II | NCT03207867 |
Inupadenant (EOS100850) | iTeos Therapeutics | A2AR antagonist | Phase I | NCT05117177 |
PBF-999 | Palobiofarma SL | A2AR antagonist | Phase I | NCT03786484 |
CS3005 | CStone Pharmaceuticals | A2AR antagonist | Phase I | NCT04233060 |
INCB106385 | Incyte Corporation | A2AR antagonist | Phase I | NCT04580485 |
EXS21546 | Exscientia Limited | A2AR antagonist | Phase I | NCT04727138 |
Etrumadenant (AB928) | Arcus Biosciences, Inc | A2AR and A2BR antagonist | Phase II | NCT04262856 |
AZD4635 | AstraZeneca | A2AR antagonist | Phase I | NCT04478513 |